Table 2.

Association between progression of chronic kidney disease and statin therapy intensity

	Model 1			Model 2		Model 3		Model 4
	Cases (%)a	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P
Low	102 (23.9)	Reference
Moderate	138 (23.2)	0.95 (0.74-1.23)	0.71	1.00 (0.77-1.29)	0.99	0.94 (0.73-1.23)	0.66	0.97 (0.72-1.30)	0.82
High	15 (30.0)	1.26 (0.73-2.17)	0.40	1.29 (0.75-2.23)	0.36	1.34 (0.77-2.34)	0.30	1.15 (0.60-2.20)	0.69

CI, confidence interval; HR, hazard ratio.

Model 1: unadjusted; Model 2: adjusted for age, sex, body mass index, and systolic blood pressure; Model 3: adjusted for Model 2 + smoking, income status, comorbidities (histories of hypertension, diabetes, and cardiovascular disease); Model 4: adjusted for Model 3 + laboratory factors (estimated glomerular filtration rate; proteinuria; lipid profiles including triglycerides, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol) and use of other lipid-lowering agents (ezetimibe or fibrate).

^aP for trend = 0.74.